21st.BIO obtains self-affirmed GRAS status for its precision fermented beta-lactoglobulin: 21st.BIO customers can now enter the U.S. market with their own production using 21st.BIO technology

Contributed by: PR Newswire

Tags

21st.BIO-GRAS-status

More Like This

21ST.BIO OPENS A MORE SUSTAINABLE AVENUE FOR INDUSTRIAL SCALE DAIRY PROTEIN PRODUCTION

21st.BIO unveils a new pilot plant facility to accelerate impact of biotech innovations globally

Onego Bio Submits Formal GRAS Notification to FDA for Bioalbumen®

PR Newswire associated0

Angel Group's First Industrialized Strain of Probiotics Anchors Strategic Transformation Towards Biotechnology

ACCESSWIRE associated0

Moolec Becomes First Molecular Farming Company to Achieve USDA Approval for Plant-Grown Animal Proteins

Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress

PR Newswire associated0

Lesaffre acquires a majority stake in Biorigin to strengthen and broaden its savory ingredients offering

Human-Residential Bifidobacteria (HRB) strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63, significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1). Subsequently, the research demonstrated that HRB strains can convert the potentially harmful indole into tryptophan (Trp) and beneficial indole-3-lactate (ILA) (Figure 2). The study also identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3), highlighting the sophisticated mechanisms by which specific HRB strains contribute to gut health. (Graphic: Business Wire)

Morinaga Milk’s New Research Breakthrough Backed the Superiority of its Human-Residential Bifidobacteria (HRB) Strains in Metabolizing Toxin Precursor in the Gut